sident, Chief Financial Officer & Business Development
Phone: (713) 660-3514
dtusa@sharpsinc.com
- OR -
Tammy Poblete
Kei Advisors LLC
Investor Relations
Phone: (716) 843-3853
Email: tpoblete@keiadvisors.com
FINANCIAL TABLES FOLLOW.
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
Consolidated Statements of Income
(unaudited)
Three-Months Ended
September 30,
2008 2007 % Change
Revenue $4,269,536 $3,391,112 25.9%
Cost of revenue 2,420,360 1,957,735 23.6%
Gross profit 1,849,176 1,433,377 29.0%
Gross margin 43.3% 42.3%
SG&A expense 1,162,954 1,155,381 0.7%
Depreciation and amortization 76,380 57,697 32.4%
Operating income (loss) 609,842 220,299 176.8%
Operating margin 14.3% 6.5%
Other income 14,871 26,302 (43.5%)
Net income before income taxes 624,713 $246,601 153.3%
Income taxes (19,372) (4,997)
Net income $605,341 $241,604 150.6%
Net income per share
Basic $0.05 $0.02
Diluted $0.04 $0.02
Weighted Average Shares Outstanding
Basic 12,662,408 12,061,734
'/>"/>SOURCE Sharps Compliance Corp. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine news :1.
Sharps Compliance Corp. Announces Results for Third Quarter of Fiscal Year 20082.
Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations3.
Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona4.
Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 20085.
Sharps Compliance Corp. Announces New Senior Vice President of Sales and Marketing6.
Sharps Compliance Corp. Announces First Quarter Fiscal Year 2008 Conference Call and Webcast7.
Genaera Receives Non-Compliance Notice From NASDAQ8.
Plexus Online Enhances Functions for Medical Device Manufacturing Regulatory Compliance9.
MED3OOO Appoints Angela Hoffman as Chief Compliance Officer10.
Cell Therapeutics Regains Compliance with NASDAQs Minimum Bid Price Requirement11.
DIA Conference to Present Latest Strategies in Clinical Trial Disclosure Compliance